Literature DB >> 14677080

Neurotransmitter changes by interferon-alpha and therapeutic implications.

M Schaefer1, M Schwaiger, M Pich, K Lieb, A Heinz.   

Abstract

Interferon alpha (IFN-alpha) is a cytokine that is widely used for the treatment of chronic viral infection or malignant disorders. During treatment with IFN-alpha, severe neuropsychiatric syndromes may occur such as depression with suicidal ideation, paranoid psychoses or confusional states. The neurobiological correlates of these side effects are widely unknown. Besides induction of other cytokines and hormonal changes, IFN-alpha has been shown to modulate the opioid, serotonin, dopamine and glutamate neurotransmitter system. Positive therapeutic effects of antidepressants such as selective serotonin-reuptake-inhibitors (SSRI) or of opioid receptor antagonists support the hypothesis that neurotransmitter changes play an important role in the development of IFN-alpha associated neuropsychiatric side effects. We review recent research about IFN-associated neurotransmitter changes in the central nervous system and discuss treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677080     DOI: 10.1055/s-2003-45131

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  19 in total

1.  Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior.

Authors:  Elisabeth G Vichaya; Phillip S Gross; Darlene J Estrada; Steve W Cole; Aaron J Grossberg; Scott E Evans; Michael J Tuvim; Burton F Dickey; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2019-02-26       Impact factor: 4.530

2.  Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Authors:  Joseph Rasimas; Antonios Katsounas; Haniya Raza; Alison A Murphy; Jun Yang; Richard A Lempicki; Anu Osinusi; Henry Masur; Michael Polis; Shyam Kottilil; Donald Rosenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

3.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

4.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

5.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

6.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

Review 7.  Neurobehavioral effects of interferon therapy.

Authors:  Alan D Valentine; Christina A Meyers
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 8.  Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV.

Authors:  Jeffrey J Weiss; Jack M Gorman
Journal:  Curr HIV/AIDS Rep       Date:  2006-11       Impact factor: 5.071

9.  Effects of cytokines and infections on brain neurochemistry.

Authors:  Adrian J Dunn
Journal:  Clin Neurosci Res       Date:  2006-08

Review 10.  Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder.

Authors:  Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2009-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.